Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 5/20 | 0.56 |
| ▸ | SLC2A4 | P14672 | 2/20 | 0.56 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.49 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.49 |
| ▸ | TSPO | P30536 | 1/20 | 0.49 |
| ▸ | PTGES | O14684 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | SLC2A8 | Q9NY64 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24343905 | 0.90 | SLC2A1 (0.51) | SLC2A1SLC2A4HSD17B2TSHRPOLB | |
| SCHEMBL24344602 | 0.85 | ALDH1A1 (0.58) | SLC2A1SLC2A4TSHRPOLBLPAR1 | |
| SCHEMBL9416588 | 0.83 | HSD17B2 (0.57) | SLC2A1SLC2A4HSD17B2TSPOPTGES | |
| SCHEMBL6990355 | 0.82 | SLC2A1 (0.61) | SLC2A1SLC2A4HSD17B2POLBHPGD | |
| SCHEMBL24343509 | 0.81 | HSD17B2 (0.45) | SLC2A1SLC2A4HSD17B2POLBHPGD | |
| SCHEMBL31150696 | 0.81 | HSD17B2 (0.45) | SLC2A1SLC2A4HSD17B2POLBHPGD | |
| SCHEMBL24343532 | 0.81 | SLC2A1 (0.63) | SLC2A1SLC2A4HSD17B2POLBHPGD | |
| SCHEMBL29234302 | 0.80 | TSHR (0.57) | SLC2A1SLC2A4HSD17B2TSHRLPAR1 | |
| SCHEMBL29469525 | 0.80 | TSHR (0.57) | SLC2A1SLC2A4HSD17B2TSHRLPAR1 | |
| SCHEMBL24344639 | 0.79 | HSD17B2 (0.56) | SLC2A1SLC2A4HSD17B2TSPOPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220118086-A1 | INTEGRIN AGONISTS OR ACTIVATING COMPOUNDS AND METHODS FOR MAKING AND USING SAME | 7 Hills Pharma LLC (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220118086-A1 | INTEGRIN AGONISTS OR ACTIVATING COMPOUNDS AND METHODS FOR MAKING AND USING SAME | ICOS, CD47, CD274 | SLC2A1 2294/4885SLC2A4 2813/4885HSD17B2 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.